It will be the numbers that dominate the debate on Monday. We are still in a cash-burn situation so however many good opportunities we have unless we can get them to pay we're just potential buzzard bait. Rights issue? |
Well if there are any market moving surprises in store for us on Monday the market doesnt seem to be expecting them. |
 Yes we are:
Yes, Oxford Biomedica is indeed involved in the production of lentiviral vectors for KYV-101. Kyverna Therapeutics has a formal agreement with Oxford Biomedica to utilize their LentiVector® platform for KYV-101, which is a CAR T-cell therapy targeting autoimmune diseases like lupus nephritis. Multiple sources confirm that Oxford Biomedica is responsible for supplying the lentiviral vectors that are integral to the development of KYV-101 [oai_citation:2,Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform | Kyverna Therapeutics](hxxps://kyvernatx.com/press-releases/kyverna-oxford-biomedica-sign-license-and-supply-agreement-for-lentivector-platform/) [oai_citation:1,Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector Platform - MarketScreener](hxxps://www.marketscreener.com/quote/stock/OXFORD-BIOMEDICA-PLC-43524070/news/Kyverna-Therapeutics-and-Oxford-Biomedica-Sign-License-and-Supply-Agreement-for-LentiVector-Platform-44895795/). |
Day number 4 on my countdown pb. They are on a PR offensive. If any of their lines eventually works out then happy days. |
Apologies, it's a bad linkHTTps://ir.kyvernatx.com/news-releases/news-release-details/kyverna-therapeutics-presents-patient-data-reinforcing-potential |
Not sure if we're involved?HTTps://ir.kyvernatx.com/news-releases/news-release-details/kyverna-therapeutics-presents-patient-data-reinforcing-potentialpHTTps://kyvernatx.com/press-releases/kyverna-oxford-biomedica-sign-license-and-supply-agreement-for-lentivector-platform/ |
OXB...a much better company than Oxford Biomedica ever was! |
What a waste of energy and money.
It makes no difference at all.
We need the phonejacker call asking to speak to the see-yeeeeyo of oxber
My Pa used to ask me why I wrote WALOB in my journal when attending pointless meetings. |
Market doesn't like companies that put their efforts into fripperies such as name/logo/etc. changing. |
After that damp squib, 3 working days to go and my selection for bronze position is GeoVax.
Some of you will remember, but back in April Phil was awarded the thread "floppy ears and wet nose" badge (with oakleaves), which is only presented rarely for sniffing out something important which everybody else has missed.
ABL Europe (then Oxford Biomedica Europe for less than a year and presumably now just OXB squiggle) are the MVA (Modified Vaccinia Ankara vector) manufacturer for GeoVax. Basically GEO-CM04S1 for universal covid and GEO-MVA for smallpox / monkeypox as far as we are concerned.
Important to point out here that the MVA doesn't belong to OXB (nee ABL Europe) in exactly the same way that the AV in Oxford University / Astra's covid vaccine didn't belong to OXB either - but there was an awful lot of money to be made in simply manufacturing it.
GeoVax recent H1 results 6th August
Selected quotes:-
"Vaccine Manufacturing Process Development
Produced first lot of GEO-CM04S1 with a commercial manufacturing platform, a critical step toward implementation of a validated chicken embryonic fibroblast (CEF) based production system for the company’s MVA-based vaccines. This milestone marks the successful completion of the transfer and scale-up of manufacturing from the research-focused Center for Biomedicine & Genetics at City of Hope to Oxford Biomedica, the Company’s cGMP (current Good Manufacturing Procedures) manufacturing partner."
(and)
"Second Quarter Business Achievements
GEO-CM04S1
Received BARDA Project NextGen award through the Rapid Response Partnership Vehicle (RRPV) to advance development of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine, in a Phase 2b clinical trial. The direct award to GeoVax of approximately $24.3 million, which may increase to as much as $45 million, will fund the manufacturing of clinical materials and support for the Phase 2b clinical trial, including regulatory activities.
Under the agreement, GeoVax will sponsor a 10,000-participant, randomized, Phase 2b double-blinded study to compare the efficacy, safety, and immunogenicity of GEO-CM04S1 with a U.S. Food and Drug Administration (FDA) approved mRNA COVID-19 vaccine. Preparations for the study are underway, and execution of the study will be funded by BARDA under its Clinical Studies Network.
The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS).
Funding for this award is provided under Project NextGen, a $5 billion initiative by HHS to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19 than the first generation COVID vaccines and medicines."
Me again (I've finished quoting) and I realise I'm pointing out the obvious here (sorry), but in the first copied passage we learn that scale up and transfer to OXB was complete and in the second passage the amount of government money they have already been awarded to fund clinical trial material and trials. In other words that's a given and old ABL Europe / new OXB squiggle will very soon be earning a lot of money from that - possibly eventually topping what we paid for the whole company on just this contract alone.
I'd strongly recommend listening to the boss of GeoVax as he is a very good speaker. This is the latest presentation only days ago at the HCW conference you can type anything in the registration boxes (I did) well worth 20 mins of your time to hear how the US government are currently throwing money at this plus much more.
GeoVax have 3 priority programmes two of which are MVA of interest to us (universal covid and the disease formally known as monkey pox).
Both are Smallpox base jabs modified for Monkeypox with the universal covid jab being a second add-on i.e. if you opt for the covid jab you get mpox / smallpox for free.
Usual caveats here that I am an OXB squiggle armband wearer and not a scientist / medic, but it strikes me that there is potential for an awful lot of money on the table here for the manufacturer of a universal covid vaccine which also protects you from monkeypox - hence place number 3 on the countdown. |
I have to say Dom, that I'm less than thrilled.
This will cost a small fortune in changing everything which has our name / logo on it and a lot of paper stuff (admittedly that's a lot less than it used to be these days) will just go straight into the skip. They've doubtless also paid someone a small fortune to come up with the new font / squiggle.
The slight upside is it's an indication that Frank has a "big show" planned for Monday.
The downside for me (and I know that you will remember this one well) is that once British Petroleum's global ambitions reached America, they were basically forced to drop the British link as there was no way the Americans were going to allow that name after the quasi merger with a US giant.
That of course lasted until the Deepwater Horizon disaster when you couldn't stop the greatest president who ever lived from referring to BP as British Petroleum something like 15 times in one press conference.
I hope there's not an American merger coming - but I think Novo would put their foot down if it was. |
Well that should fix the undervaluing..... just what we have all been waiting for. |
Oovarvo - (vic reeves) |
Excelcia!? |
At least it's not Consignia... |
They are recognised through the industry as OXB, so makes sense to me. They obviously don’t think the Oxford name adds any prestige within biotech. ‘Oxford’ probably seems stuffy, old fashioned and ‘anti-agile217; to the Americans so probably makes sense. We are on a global footprint now, not just UK business. |
Strange rebranding? Dropping "Oxford" and "Biomedica" for it's ticker symbol? If you wanted to rebrand wouldn't you go all out for a more imaginative name? |
Massive news OXB to be rebranded as .....OXB Oxford Biomedica PLC - Oxford Biomedica rebrands as OXB #OXB @OxfordBioMedic HTTps://www.voxmarkets.co.uk/rns/announcement/fb9007be-a7ed-43e6-8720-896f246c7ded #voxmarkets |
P - I really don't know - I do wish Beam would make it clearer. I have a selection of papers to read :¬( but it will have to wait for tomorrow or later. At the moment I'm wondering whether electroporation is used to prepare the package, and the lentivirus to deliver it to the patient.
It's fabulous science though - I started on this: this morning - hard work, but fascinating stuff. I wonder where it will all lead... |
Congratulations Harry. You probably haven't noticed but on every day that since you've been opening your Advent Calendar buy volume has exceeded sales. We need you on the Board as a non exec! |
supernumerary, I think you have sorted it out - It is a 2 stage process. T cells are base-edited with various things to make them invisible to the host (to make them allogenic), then transduced with a lentiviral vector to add the anti-CD7 CAR. |
Page 121 of this presentation for example: But later on P18 mentions a Lentiviral CAR, so I think there may be a step in the process I don't understand. To put it mildly :¬) |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
